Implementation of “Clinical Sequencing” in Cancer Genome Medicine in Japan.
Cancer Sci. 2017 Dec 29;:
Authors: Kohno T
In oncology, actionable mutations (alterations) in cancer-associated genes are critical in terms of the selection of therapeutic approaches. Next-generation sequencing (NGS) of tumor sample DNA (i.e., clinical sequencing) can guide clinical management by providing diagnostic or prognostic data, and facilitating the identification of potential treatment regimens, such as molecular-targeted and immune checkpoint blockade therapies. In the U.S., a variety of tumor-profiling multiplex gene panels have been developed and implemented for this purpose. In Japan, several academic institutions have now performed detailed investigations of the feasibility and value of clinical sequencing, and cancer societies have issued consensus clinical practice guidelines for NGS-based gene panel tests. These efforts will facilitate the implementation of cancer genome medicine in Japan. This article is protected by copyright. All rights reserved.
PMID: 29285848 [PubMed – as supplied by publisher]